CA-CREATORIQ
21.9.2021 14:02:26 CEST | Business Wire | Press release
Influencer marketing platform, CreatorIQ — the most trusted partner advancing the creator economy for brands like AB InBev, Disney, Sephora, and Unilever — today announced the acquisition of the #1 influencer marketing analytics platform, Tribe Dynamics .
The deal brings together Tribe Dynamics’ advanced analytics and benchmarking solutions — the industry standard for beauty and fashion brands like Estee Lauder, Fashion Nova, and LVMH — with the ability to make those insights actionable through CreatorIQ’s Creator Intelligence Cloud.
The combined company will extend CreatorIQ’s leadership position as the largest influencer marketing SaaS platform in terms of revenue, growth, data authority, and global expansion with over 450 customers, 250 employees, and $90 million in funding. The companies provide an end-to-end solution for marketers to find, activate, manage and measure their creator relationships. As influencer marketing continues to grow in size, scope, and maturity, brands need industry-standard models and data along with a 360-degree view of performance. CreatorIQ is leading the way to establish these standards and bring a new level of sophistication to the space at large.
“We are thrilled to be acquiring such a fast-growing, authoritative leader in Tribe Dynamics. With this union, CreatorIQ is accelerating our focus on advanced data science and analytics,” said Igor Vaks, Founder & CEO at CreatorIQ. “Applying Tribe Dynamics’ proprietary models, which are the standard in the beauty & fashion industries, to additional verticals will allow us to offer analytics and measurement benchmarks for the entire industry. This partnership raises the bar for what leaders should expect from an influencer marketing platform.”
“This is a big deal. Tribe Dynamics coming together with CreatorIQ is more than just two influencer marketing leaders joining forces with complementary strengths. It’s a profound opportunity to create standards for the entire influencer marketing sector and represents a multi-billion dollar market opportunity,” said Conor Begley, President at Tribe Dynamics. “Together, we will represent the unquestioned leader in the market and we are committed to serving the needs of brands across the globe as they invest in influencer marketing.”
CreatorIQ has seen rapid growth and customer expansion for the last five years, and is fresh off a round of new funding, adding another $40 million to its balance sheet. The new funding round was led by previous investors TVC Capital, Kayne Partners Fund, the growth private equity group of Kayne Anderson Capital Advisors, Affinity Group, and Unilever Ventures. Silver Lake Waterman joined the effort as a new investor in the company.
At the time of acquisition, Tribe Dynamics was in a period of rapid growth with new bookings growing over 100% YoY with a 110% net retention rate in the first half of 2021.
The transaction is expected to close in Fall 2021, after which Tribe Dynamics will continue to operate as an independent company for the foreseeable future. Cooley LLC represented CreatorIQ as counsel in the transaction, while Perkins Coie served as counsel for Tribe Dynamics. Truist served as the investment bank for Tribe Dynamics.
About CreatorIQ
CreatorIQ is the most trusted software to unify and power advanced influencer marketing for the world’s most innovative enterprises. Its Intelligence Cloud facilitates data science-enabled creator discovery, streamlines workflow, ensures brand safety, and drives meaningful measurement. AB InBev, Airbnb, Calvin Klein, CVS, Disney, H&M, Sephora, and Unilever are just some of the brands that utilize CreatorIQ’s platform to drive real business results across their influencer marketing ecosystems.
Founded in 2014, CreatorIQ is headquartered in Los Angeles with offices in San Francisco, Denver, Austin, Detroit, Chicago, Toronto, Miami, New York City, London, Auckland and Kharkiv (UA). For more information, visit CreatorIQ.com .
About Tribe Dynamics
Tribe Dynamics is the leading influencer marketing platform helping passion driven brands drive digital earned media. Its clientele includes the world’s top-performing brands on social media, such as Gucci, Sephora, Colourpop, Fashion Nova, Drunk Elephant, and Burberry. Recently, Tribe Dynamics was recognized as the #2 highest rated and #1 Easiest to Use platform on G2, out of 180 platforms that received reviews. With team members based in San Francisco, New York, and London, Tribe Dynamics works with brands across the Americas, EMEA and APAC. For more information, visit TribeDynamics.com and sign up for Earned Summit 3.0 , a free one day virtual event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005167/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
